bioAffinity Technologies, Inc. (BIAF) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Diagnostics & Research 산업에서 운영. 본사 소재지는 San Antonio, TX, 미국. 현재 CEO는 Maria Zannes.
BIAF 을(를) 보유 IPO 날짜 2022-09-01, 57 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $12.64M.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
